Pashna N. Munshi

Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial

Caron A. Jacobson, Julio C. Chávez, Alison R. Sehgal et al. · The Lancet Oncology · 2021 · 574 citations

Lymphoid Neoplasia, Axicabtagene Ciloleucel, Medicine +8

Mobilized Peripheral Blood Stem Cells Versus Unstimulated Bone Marrow As a Graft Source for T-Cell–Replete Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide

Asad Bashey, Mei-Jie Zhang, Shannon R. McCurdy et al. · Journal of Clinical Oncology · 2017 · 321 citations · Full text

Immunology, Biomedical Engineering, Immunotherapy +16

Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5)

Sattva S. Neelapu, Julio C. Chávez, Alison R. Sehgal et al. · Blood · 2023 · 118 citations · Full text

Immunodeficiencies, Immunology, Pathology +19

Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission

Mazyar Shadman, Marcelo C. Pasquini, Kwang Woo Ahn et al. · Blood · 2021 · 106 citations · Full text

Primary Analysis of Zuma-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)

Caron A. Jacobson, Julio C. Chávez, Alison R. Sehgal et al. · Blood · 2020 · 105 citations